|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goessl C, Müller M, Heicappell R, Krause
H, Straub B, Schrader M and Miller K: DNA-based detection of
prostate cancer in urine after prostatic massage. Urology.
58:335–338. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang Y, Fan C, Yu J and Wang X: APC
methylation predicts biochemical recurrence of patients with
prostate cancer: A meta-analysis. Int J Clin Exp Med.
8:15575–15580. 2015.PubMed/NCBI
|
|
5
|
Brocks D, Assenov Y, Minner S, Bogatyrova
O, Simon R, Koop C, Oakes C, Zucknick M, Lipka DB, Weischenfeldt J,
et al ICGC Early Onset Prostate Cancer Project, : Intratumor DNA
methylation heterogeneity reflects clonal evolution in aggressive
prostate cancer. Cell Reports. 8:798–806. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hoque MO, Begum S, Topaloglu O, Jeronimo
C, Mambo E, Westra WH, Califano JA and Sidransky D: Quantitative
detection of promoter hypermethylation of multiple genes in the
tumor, urine, and serum DNA of patients with renal cancer. Cancer
Res. 64:5511–5517. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bickers B and Aukim-Hastie C: New
molecular biomarkers for the prognosis and management of prostate
cancer-the post PSA era. Anticancer Res. 29:3289–3298.
2009.PubMed/NCBI
|
|
8
|
Martignano F, Gurioli G, Salvi S, Calistri
D, Costantini M, Gunelli R, De Giorgi U, Foca F and Casadio V:
GSTP1 Methylation and protein expression in prostate cancer:
Diagnostic implications. Dis Markers. 2016:43582922016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
García-Tobilla P, Solórzano SR,
Salido-Guadarrama I, González-Covarrubias V, Morales-Montor G,
Díaz-Otañez CE and Rodríguez-Dorantes M: SFRP1 repression in
prostate cancer is triggered by two different epigenetic
mechanisms. Gene. 593:292–301. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goltz D, Holmes EE, Gevensleben H, Sailer
V, Dietrich J, Jung M, Röhler M, Meller S, Ellinger J, Kristiansen
G, et al: CXCL12 promoter methylation and PD-L1 expression as
prognostic biomarkers in prostate cancer patients. Oncotarget.
7:53309–53320. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tai IT and Tang MJ: SPARC in cancer
biology: Its role in cancer progression and potential for therapy.
Drug Resist Updat. 11:231–246. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kapinas K, Lowther KM, Kessler CB, Tilbury
K, Lieberman JR, Tirnauer JS, Campagnola P and Delany AM: Bone
matrix osteonectin limits prostate cancer cell growth and survival.
Matrix Biol. 31:299–307. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Said N, Frierson HF Jr, Chernauskas D,
Conaway M, Motamed K and Theodorescu D: The role of SPARC in the
TRAMP model of prostate carcinogenesis and progression. Oncogene.
28:3487–3498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shin M, Mizokami A, Kim J, Ofude M, Konaka
H, Kadono Y, Kitagawa Y, Miwa S, Kumaki M, Keller ET, et al:
Exogenous SPARC suppresses proliferation and migration of prostate
cancer by interacting with integrin β1. Prostate. 73:1159–1170.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Y, Yu Q, Cho AH, Rondeau G, Welsh J,
Adamson E, Mercola D and McClelland M: Survey of differentially
methylated promoters in prostate cancer cell lines. Neoplasia.
7:748–760. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Niskakoski A, Kaur S, Staff S,
Renkonen-Sinisalo L, Lassus H, Järvinen HJ, Mecklin JP, Bützow R
and Peltomäki P: Epigenetic analysis of sporadic and
Lynch-associated ovarian cancers reveals histology-specific
patterns of DNA methylation. Epigenetics. 9:1577–1587. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen ZY, Zhang JL, Yao HX, Wang PY, Zhu J,
Wang W, Wang X, Wan YL, Chen SW, Chen GW, et al: Aberrant
methylation of the SPARC gene promoter and its clinical implication
in gastric cancer. Sci Rep. 4:70352014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Heitzer E, Artl M, Filipits M, Resel M,
Graf R, Weißenbacher B, Lax S, Gnant M, Wrba F, Greil R, et al:
Differential survival trends of stage II colorectal cancer patients
relate to promoter methylation status of PCDH10, SPARC, and UCHL1.
Mod Pathol. 27:906–915. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen G, Tian X, Liu Z, Zhou S, Schmidt B,
Henne-Bruns D, Bachem M and Kornmann M: Inhibition of endogenous
SPARC enhances pancreatic cancer cell growth: Modulation by
FGFR1-III isoform expression. Br J Cancer. 102:188–195. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tanpure S, Boyineini J, Gnanamony M,
Antony R, Fernández KS, Libes J, Lin J, Pinson D, Joseph PA and
Gondi CS: SPARC overexpression suppresses radiation-induced HSP27
and induces the collapse of mitochondrial Δψ in neuroblastoma
cells. Oncol Lett. 13:4602–4610. 2017.PubMed/NCBI
|
|
21
|
Kordi-Tamandani DM, Moazeni-Roodi AK,
Rigi-Ladiz MA, Hashemi M, Birjandian E and Torkamanzehi A: Promoter
hypermethylation and expression profile of MGMT and CDH1 genes in
oral cavity cancer. Arch Oral Biol. 55:809–814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Herman JG, Graff JR, Myöhänen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: A novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA. 93:pp.
9821–9826. 1996; View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Socha MJ, Said N, Dai Y, Kwong J,
Ramalingam P, Trieu V, Desai N, Mok SC and Motamed K: Aberrant
promoter methylation of SPARC in ovarian cancer. Neoplasia.
11:126–135. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kristensen H, Haldrup C, Strand S,
Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov
C, Goering W, et al: Hypermethylation of the GABRE~miR-452~miR-224
promoter in prostate cancer predicts biochemical recurrence after
radical prostatectomy. Clin Cancer Res. 20:2169–2181. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Strand SH, Orntoft TF and Sorensen KD:
Prognostic DNA methylation markers for prostate cancer. Int J Mol
Sci. 15:16544–16576. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao J, Song J, Huang H, Li Z, Du Y, Cao J,
Li M, Lv S, Lin H and Gong Y: Methylation of the SPARC gene
promoter and its clinical implication in pancreatic cancer. J Exp
Clin Cancer Res. 29:282010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Podhajcer OL, Benedetti LG, Girotti MR,
Prada F, Salvatierra E and Llera AS: The role of the matricellular
protein SPARC in the dynamic interaction between the tumor and the
host. Cancer Metastasis Rev. 27:691–705. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jacob K, Webber M, Benayahu D and Kleinman
HK: Osteonectin promotes prostate cancer cell migration and
invasion: A possible mechanism for metastasis to bone. Cancer Res.
59:4453–4457. 1999.PubMed/NCBI
|
|
29
|
Yang E, Kang HJ, Koh KH, Rhee H, Kim NK
and Kim H: Frequent inactivation of SPARC by promoter
hypermethylation in colon cancers. Int J Cancer. 121:567–575. 2007.
View Article : Google Scholar : PubMed/NCBI
|
